Immunocore Holdings plc - American Depositary Shares (IMCR)
34.50
+1.21 (3.63%)
NASDAQ· Last Trade: Aug 6th, 4:18 PM EDT
Detailed Quote
Previous Close
33.29
Open
32.84
Bid
34.50
Ask
34.58
Day's Range
32.47 - 34.58
52 Week Range
27.56 - 40.71
Volume
572,931
Market Cap
1.51B
PE Ratio (TTM)
-49.29
EPS (TTM)
-0.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
563,249
Chart
About Immunocore Holdings plc - American Depositary Shares (IMCR)
Immunocore Holdings Plc is a biotechnology company that specializes in the development of innovative T cell receptor-based therapies to treat a range of diseases, including cancer and autoimmune conditions. The company focuses on harnessing the power of the immune system by creating treatments designed to engage T cells, which play a critical role in the body's defense against diseases. Through its proprietary technology platform, Immunocore aims to develop a new class of drugs that can effectively target and destroy diseased cells while minimizing impact on healthy tissues. The company's research and clinical efforts are driven by a commitment to advancing science and improving patient outcomes in areas of significant unmet medical need. Read More
Immunocore (NASDAQ:IMCR) reported continued growth for KIMMTRAK in the second quarter and first half of 2026, while advancing three late-stage melanoma trials and early-stage programs in oncology, HIV and Type 1 diabetes.
The company recorded $223 million in KIMMTRAK net sales during the first half
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, November 10, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in November.
